Impact of CYP3A5/CYP2C19 Pharmacogenetics on Clinical Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation (HCT) Using Tacrolimus/Sirolimus (Tac/Sir) as Graft Versus Host Disease (GVHD) Prophylaxis

Samer K. Khaled, Ryotaro Nakamura(City Of Hope National Medical Center), Stephen J. Forman(City Of Hope National Medical Center), Joseph Herzog(City of Hope), Sandra H. Thomas(City Of Hope National Medical Center), David Senitzer(City of Hope), Ketevan Gendzekhadze(City Of Hope National Medical Center), Joycelynne Palmer(City of Hope), Ni‐Chun Tsai(City of Hope), Sepideh Shayani(City of Hope)
Transplantation and Cellular Therapy
February 22, 2017
10.1016/j.bbmt.2017.01.027
Cited by 0

Related Papers

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study
|Blood|2000|1.6k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754